

OCD Awareness Week 2022

Pharmacological Treatment of OCD

Sepehr "Sheperd" Aziz, D.O.

Clinical Assistant Professor of Psychiatry and Behavioral Sciences
University of Southern California Keck School of Medicine
saziz@ocdsocal.org

Treatments for OCD

- 1st line
 - Cognitive Behavioral Therapy (ERP)
 - Selective Serotonin Reuptake Inhibitors
- 2nd line
 - Serotonin Norepinephrine Reuptake Inhibitors
 - Clomipramine
- 3rd line
 - Augmentation
 - Neuromodulatory techniques (TMS, DBS, ECT, DCS, Etc)

Treatments for OCD

- Cognitive Behavioral Therapy
 - Best evidence is for Exposure Response Prevention (ERP) subtype of CBT
 - Can be Individual/Family oriented
 - Requires ability to tolerate ERP
 - Works well for relapse prevention/delay longer lasting results
 - No physiological adverse effects like meds

Treatments for OCD

- Serotonin Reuptake Inhibitors
 - Best for moderate-severe OCD symptoms
 - Co-morbid disorders especially depression/anxiety/PTSD/somatic symptoms
 - Can improve symptoms sufficiently to allow for tolerance ERP
 - Adverse effects are generally tolerable
 - Nausea, GI disturbance, headache, dryness, agitation/insomnia, drowsiness, weight changes, bleeding risk, vivid dreams, sweating, sexual dysfunction, black box warning
 - Less adverse effects than Clomipramine

Optimal Treatment

- Combined treatment
 - Should always have concurrent ERP if available and tolerable due to relapse mitigation if SRI is discontinued
 - Adding SRI is useful to treat co-occurring disorders
 - Anxiety
 - Depression
 - Somatic Symptom Disorder
 - Illness Anxiety
 - PTSD

Choosing medication

SSRIs

- Prozac/Fluoxetine (7+) agitation/insomnia
- Zoloft/Sertraline (6+) agitation/insomnia
- Paxil/Paroxetine (18+) drowsy, discontinuation syndrome risk, preg risk
- Luvox/Fluvoxamine (8+) drowsy
- Lexapro/Escitalopram limited doses, discontinuation
- Celexa/Citalopram arrythmia/QTc

SNRI

- Effexor/Venlafaxine BP monitoring, drowsy,
- Pristiq/Desvenlafaxine BP, less sexual side effects than the rest
- Anafranil/Clomipramine (10+) most GI, drowsy, weight gain, arrythmia, sexual dysfunction, dryness

Efficacy of pharmacological treatment

SSRI vs SNRI vs Clomipramine

- Head-to-head comparisons between have not shown any specifically to be superior for OCD
- SNRIs have limited (venlafaxine) or no (duloxetine) <u>studies</u>, but similar mechanism as SSRIs predicts that they should have some efficacy
- SSRIs have better side effect profile than Clomipramine and better support in randomized control trials than SNRIs.

Amelioration not elimination

- In general, SSRIs and clomipramine lead to improvement in 40 to 60 percent of OCD patients.
- Average patient on adequate trial can expect a 20 to 40 percent reduction in their OCD symptoms.

Dosages of meds when treating OCD

• SSRIs

- Fluoxetine 40 to 80 mg/day
- Fluvoxamine 200 to 300 mg/day
- Paroxetine 40 to 60 mg/day
- Sertraline 50 to 200 mg/day
- Citalopram Up to 40 mg/day* (20 mg/day in patients older than 60)
- Escitalopram 20 to 40 mg/day
- Clomipramine 100 to 250 mg/day
- Venlafaxine 225 to 350 mg/day

Length of treatment

- American Psychiatric Association practice guidelines for people who respond to meds is to stay on for one to two years.
- Needs further study
 relapse rates vary widely in studies, but generally lower for those who continue on meds after resolution of symptoms.
- If the medication is discontinued, American Psychiatric Association practice guidelines recommend that it should be slowly tapered
 - (eg, 10 to 25 percent every one to two months).

What if SSRI doesn't work

- No response → switch to:
 - Different SSRI
 - About < 50% of patients will benefit from switching from one SSRI to another
 - This number diminishes as the number of failed adequate trials increase
 - Clomipramine
 - SNRI
 - Depends on individual factors
- Partial response → Augment
 - ERP if not already onboard
 - Neuroleptic (aka antipsychotics)
 - After failed trial of at least 12 weeks of max SSRI dose
 - Antipsychotic can be effective at low doses
 - antipsychotic should be terminated after one month if the patient does not show a clear benefit.
 To limit exposure to risks.

Thank You!!

saziz@ocdsocal.org